SKLB1002VEGFR2 inhibitor,potent and ATP-competitve CAS# 1225451-84-2 |
- SKLB610
Catalog No.:BCC3647
CAS No.:1125780-41-7
- PD 173074
Catalog No.:BCC3662
CAS No.:219580-11-7
- Pazopanib (GW-786034)
Catalog No.:BCC1286
CAS No.:444731-52-6
- Pazopanib Hydrochloride
Catalog No.:BCC3708
CAS No.:635702-64-6
- RAF265
Catalog No.:BCC3677
CAS No.:927880-90-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1225451-84-2 | SDF | Download SDF |
PubChem ID | 71461003 | Appearance | Powder |
Formula | C13H12N4O2S2 | M.Wt | 320.39 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | >8mg/mL in DMSO | ||
Chemical Name | 2-(6,7-dimethoxyquinazolin-4-yl)sulfanyl-5-methyl-1,3,4-thiadiazole | ||
SMILES | CC1=NN=C(S1)SC2=NC=NC3=CC(=C(C=C32)OC)OC | ||
Standard InChIKey | RQVGFDBMONQTBC-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C13H12N4O2S2/c1-7-16-17-13(20-7)21-12-8-4-10(18-2)11(19-3)5-9(8)14-6-15-12/h4-6H,1-3H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | SKLB1002 is a potent inhibitor of VEGF receptor 2 (VEGFR2) with IC50 value of 32 nM. | |||||
Targets | VEGFR2 | |||||
IC50 | 32 nM |
SKLB1002 Dilution Calculator
SKLB1002 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1212 mL | 15.606 mL | 31.212 mL | 62.4239 mL | 78.0299 mL |
5 mM | 0.6242 mL | 3.1212 mL | 6.2424 mL | 12.4848 mL | 15.606 mL |
10 mM | 0.3121 mL | 1.5606 mL | 3.1212 mL | 6.2424 mL | 7.803 mL |
50 mM | 0.0624 mL | 0.3121 mL | 0.6242 mL | 1.2485 mL | 1.5606 mL |
100 mM | 0.0312 mL | 0.1561 mL | 0.3121 mL | 0.6242 mL | 0.7803 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
SKLB1002 is a potent inhibitor of VEGF receptor 2 with IC50 value of 32 nM [1].
VEGF receptor 2 (VEGFR2) is a major receptor for vascular endothelial growth factor (VEGF) and plays an important role in angiogenesis and VEGF-stimulated proliferation, migration, and sprouting of cultured endothelial cells [1].
SKLB1002 is a potent VEGFR2 inhibitor. In human umbilical vein endothelial cells (HUVEC), SKLB1002 significantly inhibited VEGF-induced HUVEC proliferation with IC50 value of 11.9 μM. Also, SKLB1002 inhibited HUVEC migration, invasion and tube formation in a dose-dependent way. SKLB1002 (10 μM) significantly inhibited VEGF-induced phosphorylation of VEGFR2, ERK, Src and FAK [1].
In zebrafish embryos, SKLB1002 (2.5 μM) significantly inhibited the growth of intersegmental vessels. In mice bearing SW620 or HepG2 xenografts, SKLB1002 (100 mg/kg) significantly inhibited tumor volume and inhibited tumor growth by 60%. Also, SKLB1002 reduced the microvessel density [1]. In mice with 4T1 tumor, SKLB1002 significantly reduced the tumor vessel density [2].
References:
[1]. Zhang S, Cao Z, Tian H, et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res, 2011, 17(13): 4439-4450.
[2]. Shen G, Li Y, Du T, et al. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy. Neoplasma, 2012, 59(5): 486-493.
- Gelomulide B
Catalog No.:BCN6588
CAS No.:122537-60-4
- Gelomulide A
Catalog No.:BCN6580
CAS No.:122537-59-1
- DCC-2618
Catalog No.:BCC1520
CAS No.:1225278-16-9
- AG 99
Catalog No.:BCC6667
CAS No.:122520-85-8
- Naltriben mesylate
Catalog No.:BCC5683
CAS No.:122517-78-6
- Gentiside B
Catalog No.:BCN7301
CAS No.:1225022-67-2
- INK 128 (MLN0128)
Catalog No.:BCC3880
CAS No.:1224844-38-5
- GBLD 345
Catalog No.:BCC6787
CAS No.:122479-08-7
- 4-O-(3-nitropropanoyl)corollin
Catalog No.:BCC8716
CAS No.:122475-42-7
- MFZ 10-7
Catalog No.:BCC6180
CAS No.:1224431-15-5
- Paederosidic acid methyl ester
Catalog No.:BCN3439
CAS No.:122413-01-8
- Amylin
Catalog No.:BCC6017
CAS No.:122384-88-7
- Esculentoside T
Catalog No.:BCC1077
CAS No.:
- Ajugamarin G1
Catalog No.:BCN3659
CAS No.:122587-83-1
- Ajugamarin F4
Catalog No.:BCN3656
CAS No.:122587-84-2
- 11-Hydroxyrankinidine
Catalog No.:BCN4814
CAS No.:122590-03-8
- 11-Hydroxyhumantenine
Catalog No.:BCN4863
CAS No.:122590-04-9
- Garbanzol
Catalog No.:BCN6811
CAS No.:1226-22-8
- p-Anisil
Catalog No.:BCC9112
CAS No.:1226-42-2
- Thiazovivin
Catalog No.:BCC2525
CAS No.:1226056-71-8
- PKC fragment (530-558)
Catalog No.:BCC5830
CAS No.:122613-29-0
- Ajugamarin H1
Catalog No.:BCN3658
CAS No.:122616-88-0
- Ibutilide Fumarate
Catalog No.:BCC5076
CAS No.:122647-32-9
- MK3102
Catalog No.:BCC6417
CAS No.:1226781-44-7
SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy.[Pubmed:22668017]
Neoplasma. 2012;59(5):486-93.
Vascular endothelial growth factor receptor (VEGFR) or vascular endothelial growth factor (VEGF) inhibitors have shown only modest clinical activity for most tumor types when used as single agents. However, present evidence indicates that these antiangiogenic drugs can cause transient "normalization" of the tumor vasculature, thereby improving the delivery of systemic chemotherapy. We examined temporal changes in tumor vascular function in response to the novel VEGFR2 inhibitor, SKLB1002. Established tumor-bearing animals were evaluated at serial time points for treatment-associated changes in tumor vascular architecture and function. As a result, blocking VEGF signaling by SKLB1002 produced a morphologically and functionally "normalized" vascular network. Consistent with our observations, a 2.2 fold increase in intratumoral doxorubicin levels was determined with SKLB1002 pretreatment compared with administration of doxorubicin alone. Finally, combined SKLB1002 and doxorubicin exhibited significant antitumor (49% of control size) and antimetastatic effects (12% of control metastatic nodules) in vivo. Our results showed SKLB1002 induced vascular normalization and enhanced anticancer drug delivery, which were associated with the observed synergistic effect in vivo.
Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26.[Pubmed:23263406]
Clin Exp Med. 2014 May;14(2):203-13.
A de novo VEGFR2-inhibited compound SKLB1002 which is independently developed in our laboratory has been described for antiangiogenesis and displays a potent antitumor activity in vivo and in vitro. In the present investigation, we aim to prove that combination therapy of SKLB1002 with hyperthermia plays a synergy as an antitumor agent in solid tumor. In this study, we analyzed their synergetic inhibitory action on human umbilical vein endothelial cells (HUVEC), murine mammary cancer 4T1, murine colon carcinoma CT26 in vitro. Multiply-table tournament was performed to detect cell proliferation in vitro. 4T1 implantation and CT26 implantation in BALB/c mice were used to examine the activity of combination therapy of SKLB1002 with hyperthermia in vivo. Vascular density was determined by CD31 immunohistochemistry. TUNEL was used to measure apoptosis in tumor tissue. Metastasis assay was investigated via measurement of pulmonary metastasis nodules under the microscope. Potential toxicity of combination therapy was observed by histologic analysis of main organs stained with H&E. In vitro, the combination therapy significantly inhibited cell proliferation of HUVEC, 4T1 and CT26. In vivo, 4T1 and CT26 model experiments showed that combination therapy remarkably inhibited tumor growth and prolonged life span. When compared with controls, combination therapy reached 61 % inhibition index of tumor growth against CT26 and 51 % against 4T1. Moreover, it reduced angiogenesis and increased tumor apoptosis and necrosis. It was further found that combination therapy could efficiently prevent tumor from metastasizing to lung. Importantly, it had no toxicity to main organs including heart, liver, spleen, lung and kidney. Combination treatment has been proved to be a novel and strong strategy in clinical antitumor therapy. Our findings suggest that the combination therapy of SKLB1002 with hyperthermia has a synergistic antiangiogenesis, anticancer and promotion of apoptosis efficacy compared with controls. These findings could pave a new way in clinical tumor therapy.
SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.[Pubmed:21622720]
Clin Cancer Res. 2011 Jul 1;17(13):4439-50.
PURPOSE: VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment. However, currently most of these anticancer drugs suffer some adverse effects. Discovery of novel VEGFR2 inhibitors as anticancer drug candidates is still needed. EXPERIMENTAL DESIGN: In this investigation, we adopted a restricted de novo design method to design VEGFR2 inhibitors. We selected the most potent compound SKLB1002 and analyzed its inhibitory effects on human umbilical vein endothelial cells (HUVEC) in vitro. Tumor xenografts in zebrafish and athymic mice were used to examine the in vivo activity of SKLB1002. RESULTS: The use of the restricted de novo design method indeed led to a new potent VEGFR2 inhibitor, SKLB1002, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation. Western blot analysis was conducted, which indicated that SKLB1002 inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal-regulated kinase, focal adhesion kinase, and Src. In vivo zebrafish model experiments showed that SKLB1002 remarkably blocked the formation of intersegmental vessels in zebrafish embryos. It was further found to inhibit a new microvasculature in zebrafish embryos induced by inoculated tumor cells. Finally, compared with the solvent control, administration of 100 mg/kg/d SKLB1002 reached more than 60% inhibition against human tumor xenografts in athymic mice. The antiangiogenic effect was indicated by CD31 immunohistochemical staining and alginate-encapsulated tumor cell assay. CONCLUSIONS: Our findings suggest that SKLB1002 inhibits angiogenesis and may be a potential drug candidate in anticancer therapy.